PDF(Pubmed)
Abstract：
UNASSIGNED: Echinocandins are used to treat invasive candidiasis (IC), with FDA-approved doses indicated for both obese and non-obese patients. Pharmacokinetic (PK) studies have identified subtherapeutic exposure in obese patients receiving standard doses (SDs) of echinocandins. However, research on clinical outcome differences of echinocandins\' SDs between obese and non-obese patients is lacking. Therefore, this study aimed to evaluate the effectiveness of echinocandins\' SDs in obese compared to normal-weight patients with IC.
UNASSIGNED: This retrospective cohort study was conducted at King Saud University Medical City (KSUMC) from Jan 2017 to Feb 2023. The study included adult patients diagnosed with Candida infections who received ≥ 4 doses of echinocandins. Patients with body mass index (BMI) less than 18 kg/m2 were excluded from the study. The primary and secondary outcomes included the total length of stay (LOS), IC duration, frequency of clinical resolution and all-cause mortality.
UNASSIGNED: This study included 132 patients (47 obese; 85 non-obese) with a median age of 61 years. The median BMI and weight were different between the obese (34.5 kg/m2, 88 kg) and non-obese (24 kg/m2, 65 kg) groups (P= 0.01). Micafungin and caspofungin were used in 63.6% and 36.4% of patients, respectively. The total LOS and length of IC infections were similar between both groups, with median values of 29.5 days (P= 0.896) and 18 days (P = 0.160), respectively. The clinical improvement percentages were 68.1% for obese and 65.9% for non-obese patients (P= 0.797), with all-cause mortality rates at 44.7% and 42.4%, respectively (P= 0.796).
UNASSIGNED: The study found no clinical outcome differences between obese and non-obese patients, with Similar effectiveness of the echinocandins\' SDs in both groups. Further research in multi-centre settings is recommended to detect any potential differences between the two groups.
UNASSIGNED: This retrospective cohort study was conducted at King Saud University Medical City (KSUMC) from Jan 2017 to Feb 2023. The study included adult patients diagnosed with Candida infections who received ≥ 4 doses of echinocandins. Patients with body mass index (BMI) less than 18 kg/m2 were excluded from the study. The primary and secondary outcomes included the total length of stay (LOS), IC duration, frequency of clinical resolution and all-cause mortality.
UNASSIGNED: This study included 132 patients (47 obese; 85 non-obese) with a median age of 61 years. The median BMI and weight were different between the obese (34.5 kg/m2, 88 kg) and non-obese (24 kg/m2, 65 kg) groups (P= 0.01). Micafungin and caspofungin were used in 63.6% and 36.4% of patients, respectively. The total LOS and length of IC infections were similar between both groups, with median values of 29.5 days (P= 0.896) and 18 days (P = 0.160), respectively. The clinical improvement percentages were 68.1% for obese and 65.9% for non-obese patients (P= 0.797), with all-cause mortality rates at 44.7% and 42.4%, respectively (P= 0.796).
UNASSIGNED: The study found no clinical outcome differences between obese and non-obese patients, with Similar effectiveness of the echinocandins\' SDs in both groups. Further research in multi-centre settings is recommended to detect any potential differences between the two groups.
摘要：
■棘球白素用于治疗侵袭性念珠菌病（IC），FDA批准的剂量适用于肥胖和非肥胖患者。药代动力学（PK）研究已经确定了接受标准剂量（SD）棘白菌素的肥胖患者的亚治疗暴露。然而,缺乏肥胖和非肥胖患者棘白菌素类SDs临床结局差异的研究。因此,本研究旨在评估与正常体重IC患者相比,棘白菌素SDs对肥胖患者的疗效.
■这项回顾性队列研究于2017年1月至2023年2月在沙特国王大学医学城（KSUMC）进行。该研究包括诊断为念珠菌感染并接受≥4剂量棘白菌素的成年患者。体重指数（BMI）小于18kg/m2的患者被排除在研究之外。主要和次要结果包括总住院时间（LOS），IC持续时间,临床分辨率和全因死亡率的频率。
■这项研究包括132名患者（47名肥胖；85名非肥胖），中位年龄为61岁。肥胖（34.5kg/m2，88kg）和非肥胖（24kg/m2，65kg）组的BMI和体重中位数不同（P=0.01）。63.6%和36.4%的患者使用了米卡芬净和卡泊芬净，分别。两组的总LOS和IC感染长度相似，中位数分别为29.5天（P=0.896）和18天（P=0.160），分别。肥胖患者的临床改善百分比为68.1%，非肥胖患者为65.9%(P=0.797)。全因死亡率分别为44.7%和42.4%,分别为(P=0.796)。
■研究发现肥胖和非肥胖患者的临床结局没有差异，两组棘白菌素SDs的有效性相似。建议在多中心设置中进行进一步研究，以检测两组之间的任何潜在差异。
■这项回顾性队列研究于2017年1月至2023年2月在沙特国王大学医学城（KSUMC）进行。该研究包括诊断为念珠菌感染并接受≥4剂量棘白菌素的成年患者。体重指数（BMI）小于18kg/m2的患者被排除在研究之外。主要和次要结果包括总住院时间（LOS），IC持续时间,临床分辨率和全因死亡率的频率。
■这项研究包括132名患者（47名肥胖；85名非肥胖），中位年龄为61岁。肥胖（34.5kg/m2，88kg）和非肥胖（24kg/m2，65kg）组的BMI和体重中位数不同（P=0.01）。63.6%和36.4%的患者使用了米卡芬净和卡泊芬净，分别。两组的总LOS和IC感染长度相似，中位数分别为29.5天（P=0.896）和18天（P=0.160），分别。肥胖患者的临床改善百分比为68.1%，非肥胖患者为65.9%(P=0.797)。全因死亡率分别为44.7%和42.4%,分别为(P=0.796)。
■研究发现肥胖和非肥胖患者的临床结局没有差异，两组棘白菌素SDs的有效性相似。建议在多中心设置中进行进一步研究，以检测两组之间的任何潜在差异。
